{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T12:17:48Z","timestamp":1790511468450,"version":"4.1.0"},"reference-count":47,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The adage for smoldering myeloma (SMM) has been to observe without treatment, until criteria for active multiple myeloma were satisfied. Definitions and risk stratification models have become more sophisticated, with prognostication tailored to include high-risk cytogenetics as per the most recent International Myeloma Working Group 2020 risk model. Moreover, progress in defining genomic evolution and changes in the bone marrow microenvironment through the monoclonal continuum have given insight into the complexities underlying the different patterns of progression observed in SMM. Given recent data showing improved progression-free survival with early intervention in high-risk SMM, the current dilemma is focused on how these patients should be treated. This case-based article maps the significant advancements made in the diagnosis and risk stratification of SMM. Data from landmark clinical trials will also be discussed, and ongoing trials are summarized. Ultimately, we outline our approach to SMM and hope to impart to the reader a sound concept of the current clinical management of SMM.<\/jats:p>","DOI":"10.1182\/hematology.2021000304","type":"journal-article","created":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T12:21:03Z","timestamp":1639138863000},"page":"673-681","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":23,"title":["Smoldering multiple myeloma: evolving diagnostic criteria and treatment strategies"],"prefix":"10.1182","volume":"2021","author":[{"given":"Alissa","family":"Visram","sequence":"first","affiliation":[{"name":"Division of Hematology, The Ottawa Hospital, Ottawa, ON, Canada"},{"name":"Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joselle","family":"Cook","sequence":"additional","affiliation":[{"name":"Division of Hematology, The Ottawa Hospital, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahma","family":"Warsame","sequence":"additional","affiliation":[{"name":"Division of Hematology, The Ottawa Hospital, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,12,10]]},"reference":[{"issue":"24","key":"2021121012091499000_hem2021000304C1","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198006123022405","article-title":"Smoldering multiple myeloma","volume":"302","author":"Kyle","year":"1980","journal-title":"N Engl J Med"},{"issue":"10","key":"2021121012091499000_hem2021000304C2","doi-asserted-by":"crossref","first-page":"e486","DOI":"10.1038\/bcj.2016.100","article-title":"Prevalence, incidence and survival of smoldering multiple myeloma in the United States","volume":"6","author":"Ravindran","year":"2016","journal-title":"Blood Cancer J"},{"issue":"15, suppl","key":"2021121012091499000_hem2021000304C3","doi-asserted-by":"crossref","first-page":"e13064","DOI":"10.1200\/JCO.2019.37.15_suppl.e13064","article-title":"Demographic characteristics of smoldering multiple myeloma patients: a hospital-based study including 11,643 patients","volume":"37","author":"Chamoun","year":"2019","journal-title":"J Clin Oncol"},{"issue":"18","key":"2021121012091499000_hem2021000304C4","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1056\/NEJMc1310911","article-title":"Treatment for high-risk smoldering myeloma","volume":"369","author":"Kristinsson","year":"2013","journal-title":"N Engl J Med"},{"issue":"11","key":"2021121012091499000_hem2021000304C5","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.mayocp.2012.06.014","article-title":"Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition","volume":"87","author":"Therneau","year":"2012","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"2021121012091499000_hem2021000304C6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"2021121012091499000_hem2021000304C7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41408-020-0284-7","article-title":"Dissecting racial disparities in multiple myeloma","volume":"10","author":"Marinac","year":"2020","journal-title":"Blood Cancer J"},{"issue":"10","key":"2021121012091499000_hem2021000304C8","doi-asserted-by":"crossref","first-page":"e618","DOI":"10.1038\/bcj.2017.97","article-title":"Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination Survey","volume":"7","author":"Landgren","year":"2017","journal-title":"Blood Cancer J"},{"key":"2021121012091499000_hem2021000304C9","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.3389\/fonc.2019.01513","article-title":"Prevalence and incidence of multiple myeloma in urban area in China: a national population-based analysis","volume":"9","author":"Wang","year":"2020","journal-title":"Fron Oncol"},{"issue":"11","key":"2021121012091499000_hem2021000304C10","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/JCO.19.01740","article-title":"Randomized trial of lenalidomide versus observation in smoldering multiple myeloma","volume":"38","author":"Lonial","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"2021121012091499000_hem2021000304C11","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/leu.2012.296","article-title":"Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma","volume":"27","author":"Larsen","year":"2013","journal-title":"Leukemia"},{"issue":"12","key":"2021121012091499000_hem2021000304C12","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1038\/leu.2014.230","article-title":"The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma","volume":"28","author":"Kastritis","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"2021121012091499000_hem2021000304C13","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group","volume":"121","author":"International Myeloma Working Group","year":"2003","journal-title":"Br J Haematol"},{"issue":"9","key":"2021121012091499000_hem2021000304C14","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2009.25.5356","article-title":"Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma","volume":"28","author":"Hillengass","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"2021121012091499000_hem2021000304C15","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1056\/NEJMc1106428","article-title":"Diagnosis of smoldering multiple myeloma","volume":"365","author":"Rajkumar","year":"2011","journal-title":"N Engl J Med"},{"issue":"12","key":"2021121012091499000_hem2021000304C16","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"2","key":"2021121012091499000_hem2021000304C17","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/leu.2015.291","article-title":"18F-FDG PET\/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease","volume":"30","author":"Zamagni","year":"2016","journal-title":"Leukemia"},{"issue":"4","key":"2021121012091499000_hem2021000304C18","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","article-title":"Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group","volume":"18","author":"Cavo","year":"2017","journal-title":"Lancet Oncol"},{"issue":"21","key":"2021121012091499000_hem2021000304C19","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.20.00437","article-title":"Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression","volume":"38","author":"Bustoros","year":"2020","journal-title":"J Clin Oncol"},{"issue":"8","key":"2021121012091499000_hem2021000304C20","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/leu.2013.86","article-title":"Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma","volume":"27","author":"Rajkumar","year":"2013","journal-title":"Leukemia"},{"issue":"21","key":"2021121012091499000_hem2021000304C21","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1200\/JCO.20.00875","article-title":"Smoldering myeloma and the art of war","volume":"38","author":"Lonial","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"2021121012091499000_hem2021000304C22","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41375-019-0543-4","article-title":"MYC dysregulation in the progression of multiple myeloma","volume":"34","author":"Misund","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"2021121012091499000_hem2021000304C23","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41467-020-20524-2","article-title":"The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma","volume":"12","author":"Boyle","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"2021121012091499000_hem2021000304C24","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1038\/s41467-018-05058-y","article-title":"Genomic patterns of progression in smoldering multiple myeloma","volume":"9","author":"Bolli","year":"2018","journal-title":"Nat Commun"},{"issue":"2","key":"2021121012091499000_hem2021000304C25","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41375-018-0206-x","article-title":"Subclonal evolution in disease progression from MGUS\/SMM to multiple myeloma is characterised by clonal stability","volume":"33","author":"Dutta","year":"2019","journal-title":"Leukemia"},{"issue":"suppl 2","key":"2021121012091499000_hem2021000304C26","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/HS9.0000000000000246","article-title":"Bone marrow niche in multiple myeloma and its precursor states","volume":"3","author":"Sklavenitis-Pistofidis","year":"2019","journal-title":"HemaSphere"},{"issue":"5","key":"2021121012091499000_hem2021000304C27","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","article-title":"Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma","volume":"1","author":"Zavidij","year":"2020","journal-title":"Nat Cancer"},{"issue":"9","key":"2021121012091499000_hem2021000304C28","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1182\/blood-2015-10-662320","article-title":"Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis","volume":"127","author":"Paiva","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2021121012091499000_hem2021000304C29","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/leu.2012.237","article-title":"High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma","volume":"27","author":"Bianchi","year":"2013","journal-title":"Leukemia"},{"issue":"7","key":"2021121012091499000_hem2021000304C30","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"P\u00e9rez-Persona","year":"2007","journal-title":"Blood"},{"issue":"22","key":"2021121012091499000_hem2021000304C31","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1182\/bloodadvances.2018024794","article-title":"Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma","volume":"2","author":"Aljama","year":"2018","journal-title":"Blood Adv"},{"issue":"6","key":"2021121012091499000_hem2021000304C32","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria","volume":"8","author":"Lakshman","year":"2018","journal-title":"Blood Cancer J"},{"issue":"10","key":"2021121012091499000_hem2021000304C33","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)","volume":"10","author":"Mateos","year":"2020","journal-title":"Blood Cancer J"},{"issue":"1","key":"2021121012091499000_hem2021000304C34","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1001\/jamaoncol.2020.5585","article-title":"Assessment of discordance among smoldering multiple myeloma risk models","volume":"7","author":"Hill","year":"2021","journal-title":"JAMA Oncol"},{"issue":"25","key":"2021121012091499000_hem2021000304C35","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"issue":"6","key":"2021121012091499000_hem2021000304C36","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/s41375-018-0013-4","article-title":"Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression","volume":"32","author":"Fern\u00e1ndez de Larrea","year":"2018","journal-title":"Leukemia"},{"issue":"7","key":"2021121012091499000_hem2021000304C37","doi-asserted-by":"crossref","first-page":"e454","DOI":"10.1038\/bcj.2016.65","article-title":"Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma","volume":"6","author":"Ravi","year":"2016","journal-title":"Blood Cancer J"},{"issue":"3","key":"2021121012091499000_hem2021000304C38","doi-asserted-by":"crossref","first-page":"E63","DOI":"10.1002\/ajh.26062","article-title":"Dynamic follow-up of smoldering multiple myeloma identifies a subset of patients at high risk of progression","volume":"96","author":"Gran","year":"2021","journal-title":"Am J Hematol"},{"issue":"5","key":"2021121012091499000_hem2021000304C39","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","volume":"369","author":"Mateos","year":"2013","journal-title":"N Engl J Med"},{"issue":"8","key":"2021121012091499000_hem2021000304C40","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S1470-2045(16)30124-3","article-title":"Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial","volume":"17","author":"Mateos","year":"2016","journal-title":"Lancet Oncol"},{"issue":"7","key":"2021121012091499000_hem2021000304C41","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41375-020-0718-z","article-title":"Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)","volume":"34","author":"Landgren","year":"2020","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2021121012091499000_hem2021000304C42","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1182\/blood-2018-154","article-title":"Phase II trial of combination of elotuzumab, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma","volume":"132","author":"Liu","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2021121012091499000_hem2021000304C43","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1182\/blood-2018-99-117871","article-title":"Phase II trial of the combination of ixazomib, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma","volume":"132","author":"Bustoros","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2021121012091499000_hem2021000304C44","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1182\/blood-2019-123205","article-title":"A multicenter phase II single arm trial of isatuximab in patients with high risk smoldering multiple myeloma (HRSMM)","volume":"134","author":"Manasanch","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2021121012091499000_hem2021000304C45","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1182\/blood-2019-125204","article-title":"Curative strategy (GEM-CESAR) for high-risk smoldering myeloma (SMM): carfilzomib, lenalidomide and dexamethasone (KRd) as induction followed by HDT-ASCT, consolidation with Krd and maintenance with Rd","volume":"134","author":"Mateos","year":"2019","journal-title":"Blood"},{"issue":"15, suppl","key":"2021121012091499000_hem2021000304C46","doi-asserted-by":"crossref","first-page":"8512","DOI":"10.1200\/JCO.2020.38.15_suppl.8512","article-title":"Analysis of treatment efficacy in the GEM-CESAR trial for high-risk smoldering multiple myeloma patients: comparison between the standard and IMWG MRD criteria and QIP-MS including FLC (QIP-FLC-MS)","volume":"38","author":"Pu\u00edg","year":"2020","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2021121012091499000_hem2021000304C47","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2020-136148","article-title":"Treatment of high risk (HR) smoldering multiple myeloma (SMM) with carfilzomib, lenalidomide, and dexamethasone (KRd) followed by lenalidomide maintenance (-R): a phase 2 clinical and correlative study","volume":"136","author":"Kazandjian","year":"2020","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2021\/1\/673\/1851664\/673visram.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2021\/1\/673\/1851664\/673visram.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T12:21:35Z","timestamp":1639138895000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2021\/1\/673\/482954\/Smoldering-multiple-myeloma-evolving-diagnostic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,10]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12,10]]},"published-print":{"date-parts":[[2021,12,10]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2021000304","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,10]]},"published":{"date-parts":[[2021,12,10]]}}}